Becton, Dickinson and Company

(New York Stock Exchange)
Back to all articles
Somewhat Bearish -25

Becton Dickinson (BDX) Gets a Hold from Piper Sandler

AI-generated analysis

πŸ“‰ Piper Sandler analyst Jason Bednar maintained a Hold rating on Becton Dickinson (BDX) with a price target of $161.00.

πŸ“Š The current analyst consensus for BDX is a Moderate Buy with an average price target of $182.40.

πŸ’° For the quarter ending March 31, Becton Dickinson reported quarterly revenue of $4.71 billion.

πŸ“‰ GAAP net loss for the quarter was $311 million compared to a net profit of $308 million last year.

πŸ“‰ Revenue declined from $5.27 billion in the same period last year.

πŸ‘€ Analyst Jason Bednar has an average return of -5.5% and a 38.89% success rate according to Tipranks.

πŸ₯ Bednar covers the Healthcare sector including Merit Medical Systems, ICU Medical, and Align Tech.

πŸ“° The article includes syndicated content from third parties that has not been reviewed by The Globe and Mail.

πŸ’Έ Becton Dickinson issued new €600 million senior notes to refinance debt.

πŸ“ˆ Other recent news for BDX includes a price target raise to $204 at Barclays and lifting EPS outlook.

Bullish Signals
  • Becton Dickinson announced a €600 million senior notes offering to refinance debt, demonstrating proactive capital management.
  • Analyst consensus maintains a Moderate Buy rating with an average price target of $182.40, indicating overall market confidence in the stock's upside potential.
  • The company reported quarterly revenue of $4.71 billion for the quarter ending March 31, reflecting continued strong demand despite macroeconomic headwinds.
  • Becton Dickinson lifted its EPS outlook amid mixed headwinds, signaling management's commitment to improving profitability and operational efficiency.
Risk Factors
  • Piper Sandler analyst Jason Bednar maintained a Hold rating on Becton Dickinson (BDX) with a price target of $161.00, which is significantly below the current analyst consensus average price target of $182.40.
  • Analyst Jason Bednar has an average return of -5.5% and a success rate of only 38.89%, suggesting potential reliability concerns for his specific recommendations.
  • The company reported a GAAP net loss of $311 million for the quarter ending March 31, marking a sharp reversal from the previous year's net profit of $308 million.
  • Quarterly revenue declined to $4.71 billion compared to $5.27 billion in the same period last year, indicating a significant contraction in top-line growth.
Full Analysis
Piper Sandler analyst Jason Bednar maintained a Hold rating on Becton Dickinson (BDX) with a price target of $161.00, based on the company's latest earnings release for the quarter ending March 31. The company reported quarterly revenue of $4.71 billion and a GAAP net loss of $311 million, compared to last year's revenue of $5.27 billion and net profit of $308 million. This marks a significant decline in profitability and revenue for the healthcare equipment manufacturer. The analyst consensus on Becton Dickinson remains a Moderate Buy with an average price target of $182.40, indicating some divergence between individual analyst views and the broader market sentiment. Bednar covers the Healthcare sector and has previously covered other stocks such as Merit Medical Systems, ICU Medical, and Align Tech. The article also notes that Becton Dickinson issued new €600 million senior notes to refinance debt, highlighting ongoing capital management activities despite the earnings miss.